Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.53 |
| ▸ | KMO | O15229 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.45 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5863189 | 0.91 | NR4A2 (0.57) | MRGPRX4NR4A2KMONR1H4KMT2A | |
| SCHEMBL5863142 | 0.89 | PKM (0.58) | NR4A2GAARXRARXRB | |
| SCHEMBL5863160 | 0.88 | NR4A2 (0.53) | MRGPRX4NR4A2NR1H4RXRARXRB | |
| SCHEMBL5863113 | 0.87 | MEN1 (0.51) | KMT2A | |
| SCHEMBL5863212 | 0.82 | PTGER1 (0.49) | MRGPRX4NR4A2KMONR1H4KMT2A | |
| SCHEMBL5863110 | 0.81 | FYN (0.48) | LMNABCL2L1MCL1 | |
| SCHEMBL6256752 | 0.80 | DCLRE1B (0.52) | NR4A2FFAR1FFAR4MCL1 | |
| SCHEMBL5863289 | 0.80 | FYN (0.50) | LMNAKMT2A | |
| Oxalic Acid SCHEMBL5863295 | 0.80 | FYN (0.47) | LMNA | |
| SCHEMBL5863076 | 0.78 | MEN1 (0.52) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132456-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2006-11-07 | — | — | US | claimed |
| US-20060052449-A1 | Novel mch receptor antagonists | ELI LILLY AND COMPANY | 2006-03-09 | — | — | US | claimed |
| EP-1572637-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-14 | — | — | EP | claimed |
| WO-2004052848-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | claimed |
| US-7132456-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060052449-A1 | Novel mch receptor antagonists | ELI LILLY AND COMPANY | 2006-03-09 | — | — | US | disclosed |
| EP-1572637-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052848-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052449-A1 | Novel mch receptor antagonists | MCHR1, MCHR2, MC1R | MRGPRX4 90/4885NR4A2 341/4885KMO 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.